Juno Therapeutics halts Phase III ROCKET trial of JCAR015 to treat leukaemia

US-based biopharmaceutical company Juno Therapeutics has halted its Phase III ROCKET trial of JCAR015 to treat adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news